Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry
Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry
复制标题
患有房颤的透析患者的临床特征和结果：伏见 AF 登记处
DOI：
10.1007/s00380-016-0818-x
复制
发表时间：
2016
影响因子：
1.5
通讯作者：
M. Akao
中科院分区：
文献类型：
--
作者：
Y. Yamashita;D. Takagi;Y. Hamatani;M. Iguchi;N. Masunaga;M. Esato;Y. Chun;Hitoshi Itoh;M. Nishimura;H. Wada;K. Hasegawa;H. Ogawa;M. Abe;M. Akao
房颤（AF）在透析患者中很常见。然而，透析合并房颤患者的临床特征和预后尚不清楚。Fushimi房颤登记是日本房颤患者的一项基于社区的前瞻性调查。随访数据为3713例患者，中位随访时间为2.8年。我们比较了透析组（n = 92; 2.5%）和其他组的临床特征和结果。透析组各种合并症较多，CHADS2平均评分2.5分，华法林处方率为38%。透析组中风或全身性栓塞（SE）、大出血和全因死亡的年发病率分别为每100人年4.0、5.1和20.9。透析组与非透析组卒中/SE发生率无显著差异[风险比（HR） 1.74(95%可信区间（CI） 0.74 ~ 3.42)]。透析组大出血、全因死亡、卒中/SE复合及全因死亡的发生率均高于非透析组[大出血：HR 3.09 (95% CI 1.46 ~ 5.72)，全因死亡：HR 3.51 (95% CI 2.48 ~ 4.81)，卒中/SE复合及全因死亡：HR 2.99 (95% CI 2.15 ~ 4.05)]。在透析患者中，华法林不影响主要临床事件，包括中风/SE、出血或全因死亡。在房颤患者中，接受透析的患者大出血和全因死亡的发生率高于未接受透析的患者，但卒中/SE的风险并不是特别高。临床试验注册网址：http://www.umin.ac.jp/ctr/index.htm。
Atrial fibrillation (AF) is common in dialysis patients. However, clinical characteristics and outcomes of dialysis patients with AF are poorly understood. The Fushimi AF Registry is a community-based prospective survey of AF patients in Japan. Follow-up data were available for 3713 patients with a median follow-up of 2.8 years. We compared clinical characteristics and outcomes between the dialysis group (n = 92; 2.5 %) and others. The dialysis group had more various co-morbidities, with a mean CHADS2 score of 2.5, and the rate of warfarin prescription was 38 %. The annual incidence rates of stroke or systemic embolism (SE), major bleeding, and all-cause death in the dialysis group were 4.0, 5.1, and 20.9 per 100 person-years, respectively. There was no significant difference in the incidence rate of stroke/SE between the dialysis group and the non-dialysis group [hazard ratio (HR) 1.74 (95 % confidence interval (CI) 0.74–3.42)]. The incidence rates of major bleeding, all-cause death, and the composite of stroke/SE and all-cause death in the dialysis group were higher than those in the non-dialysis group [major bleeding: HR 3.09 (95 % CI 1.46–5.72), all-cause death: HR 3.51 (95 % CI 2.48–4.81), the composite of stroke/SE and all-cause death: HR 2.99 (95 % CI 2.15–4.05)]. Among dialysis patients, warfarin did not affect major clinical events including stroke/SE, bleeding or all-cause death. Among AF patients, those receiving dialysis showed higher incidence of major bleeding and all-cause death compared with non-dialysis patients, but the risk of stroke/SE was not particularly high.Clinical trial registrationURL: http://www.umin.ac.jp/ctr/index.htm.
影响因子：
8.3
作者：
WOLF, PA;ABBOTT, RD;KANNEL, WB
通讯作者：
KANNEL, WB